Agilent Technologies (NYSE:A) Given New $150.00 Price Target at Wells Fargo & Company

Agilent Technologies (NYSE:A) had its price target increased by Wells Fargo & Company from $140.00 to $150.00 in a research note issued to investors on Monday,Benzinga reports. They currently have an overweight rating on the medical research company’s stock.

A number of other equities analysts also recently commented on A. Barclays restated an “equal weight” rating and issued a $125.00 target price on shares of Agilent Technologies in a research note on Friday, August 29th. UBS Group reduced their price objective on Agilent Technologies from $150.00 to $130.00 and set a “neutral” rating for the company in a research report on Thursday, May 29th. TD Cowen boosted their price objective on Agilent Technologies to $150.00 and gave the stock a “buy” rating in a research report on Thursday, May 29th. Wall Street Zen downgraded Agilent Technologies from a “buy” rating to a “hold” rating in a research report on Friday, September 5th. Finally, Evercore ISI reduced their price objective on Agilent Technologies from $130.00 to $128.00 and set an “in-line” rating for the company in a research report on Thursday, August 28th. Six analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $140.08.

Agilent Technologies Stock Performance

Shares of A stock opened at $125.68 on Monday. The company has a quick ratio of 1.71, a current ratio of 2.25 and a debt-to-equity ratio of 0.53. The business has a 50 day moving average of $119.89 and a two-hundred day moving average of $115.77. Agilent Technologies has a 52 week low of $96.43 and a 52 week high of $153.84. The company has a market cap of $35.63 billion, a P/E ratio of 29.50, a PEG ratio of 3.83 and a beta of 1.24.

Agilent Technologies (NYSE:A) last issued its earnings results on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, meeting analysts’ consensus estimates of $1.37. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The company had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.67 billion. During the same period in the previous year, the firm posted $1.32 earnings per share. Agilent Technologies’s quarterly revenue was up 10.1% compared to the same quarter last year. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, analysts anticipate that Agilent Technologies will post 5.58 EPS for the current year.

Insider Transactions at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of the company’s stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total transaction of $177,099.52. Following the completion of the sale, the chief executive officer directly owned 37,448 shares in the company, valued at $4,397,893.12. This represents a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Verdence Capital Advisors LLC raised its position in shares of Agilent Technologies by 5.0% during the second quarter. Verdence Capital Advisors LLC now owns 1,818 shares of the medical research company’s stock valued at $215,000 after buying an additional 86 shares during the last quarter. M&T Bank Corp raised its position in shares of Agilent Technologies by 0.4% during the second quarter. M&T Bank Corp now owns 23,205 shares of the medical research company’s stock valued at $2,738,000 after buying an additional 86 shares during the last quarter. CENTRAL TRUST Co raised its position in shares of Agilent Technologies by 3.7% during the second quarter. CENTRAL TRUST Co now owns 2,522 shares of the medical research company’s stock valued at $298,000 after buying an additional 89 shares during the last quarter. Burney Co. raised its position in shares of Agilent Technologies by 4.8% during the second quarter. Burney Co. now owns 1,957 shares of the medical research company’s stock valued at $231,000 after buying an additional 90 shares during the last quarter. Finally, Valeo Financial Advisors LLC raised its position in shares of Agilent Technologies by 3.0% during the first quarter. Valeo Financial Advisors LLC now owns 3,449 shares of the medical research company’s stock valued at $403,000 after buying an additional 102 shares during the last quarter.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.